The FDA recently has approved the topical treatment, oxymetazoline hydrochloride (Rhofade, Allergan plc) cream, for patients with persistent facial erythema associated with rosacea in adults.

Mirvaso is the first and only FDA-approved topical treatment for persistent erythema of rosacea. The FDA approved Mirvaso (brimonidine) Topical Gel, 0.33% in August 2013 as the first and only topical treatment indicated for the persistent (non-transient) facial erythema of rosacea in adults age 18 or older. The gel, marketed by Galderma Laboratories, L.P., is an alpha-2 adrenergic agonist that may work by constricting the dilated blood vessels to reduce the redness of rosacea.